This new type of super-precise radiotherapy promises to transform the way we treat certain types of lung cancer, after a Melbourne-led clinical trial revealed the treatment significantly improved survival chances.
Stereotactic ablative body radiotherapy (SABR) uses thin beams of radiation to directly attack the tumour. It's also cheaper than traditional radiotherapy.
In this way, the tumour receives a very high dose of radiation and the surrounding tissues largely avoid it, minimising side effects. And patients only need to come to hospital three or four times, rather than regularly over the space of two months.